Moderna | Times Square Investment Journal

Moderna will ride drug money (and your tax dollars) right out of the red

by Suzannah Cavanaugh | Dec 16, 2020

This time last year, Moderna, Inc., was starting to look a lot like Theranos. Moderna had spent the large part of a decade selling investors on the idea of an unprecedented product—a messenger RNA drug. The company, valued at $7.5 billion, made history in December...

Moderna’s trial diversity is all for show if Black and Brown Medicaid recipients can’t afford a vaccine

by Suzannah Cavanaugh | Oct 30, 2020

In the Covid-19 vaccine race, Moderna, Inc. made headlines last week for the representative diversity of its trial candidates. The company touted 37% enrollment by people of color in late-stage trials, a figure that nearly mirrors the 40% of the population U.S....

Moderna says vaccine produces antibodies in seniors, pushes ahead in Warp Speed race

by Suzannah Cavanaugh | Oct 2, 2020

Moderna Inc. announced Tuesday that its Covid-19 vaccine candidate had generated levels of virus-neutralizing antibodies in older adults on par with those produced in younger trial participants, a crucial step towards approval. The early-stage result gives Moderna a...